Free Trial

Stoke Therapeutics (STOK) Competitors

Stoke Therapeutics logo
$13.51 -0.76 (-5.33%)
Closing price 04:00 PM Eastern
Extended Trading
$13.58 +0.06 (+0.48%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STOK vs. ARWR, IBRX, OGN, APLS, XENE, NAMS, GMTX, BHC, AGIO, and TWST

Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

Stoke Therapeutics vs. Its Competitors

Stoke Therapeutics (NASDAQ:STOK) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Stoke Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$36.56M20.18-$88.98M$0.7917.10
Arrowhead Pharmaceuticals$3.55M632.54-$599.49M-$1.40-11.61

Stoke Therapeutics currently has a consensus price target of $25.80, suggesting a potential upside of 90.97%. Arrowhead Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 168.85%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Arrowhead Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Stoke Therapeutics has a net margin of 26.33% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Stoke Therapeutics' return on equity of 19.08% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics26.33% 19.08% 15.72%
Arrowhead Pharmaceuticals N/A -45.33%-12.49%

In the previous week, Stoke Therapeutics and Stoke Therapeutics both had 10 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 0.82 beat Stoke Therapeutics' score of 0.60 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arrowhead Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Stoke Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Summary

Stoke Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STOK vs. The Competition

MetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$779.10M$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio17.1020.7327.9019.95
Price / Sales20.18321.07442.18102.66
Price / CashN/A43.2336.5558.97
Price / Book3.138.308.635.90
Net Income-$88.98M-$55.19M$3.24B$258.42M
7 Day Performance9.39%5.07%3.22%1.94%
1 Month Performance17.38%17.61%10.72%12.02%
1 Year Performance-5.39%7.03%34.94%20.81%

Stoke Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STOK
Stoke Therapeutics
4.2387 of 5 stars
$13.51
-5.3%
$25.80
+91.0%
-2.1%$779.10M$36.56M17.10100
ARWR
Arrowhead Pharmaceuticals
3.879 of 5 stars
$18.61
+1.6%
$43.71
+134.9%
-44.7%$2.57B$545.21M-13.29400
IBRX
ImmunityBio
2.0236 of 5 stars
$2.90
+3.2%
$12.25
+322.4%
-47.1%$2.56B$31.22M-5.00590
OGN
Organon & Co.
4.7622 of 5 stars
$9.83
-1.2%
$18.00
+83.2%
-53.0%$2.55B$6.40B3.414,000
APLS
Apellis Pharmaceuticals
4.3205 of 5 stars
$19.91
+2.4%
$39.79
+99.8%
-46.0%$2.50B$781.37M-11.12770Upcoming Earnings
XENE
Xenon Pharmaceuticals
3.7751 of 5 stars
$32.60
+1.2%
$54.82
+68.2%
-28.8%$2.50B$9.43M-10.09210Positive News
Options Volume
NAMS
NewAmsterdam Pharma
3.632 of 5 stars
$22.17
+2.9%
$42.89
+93.5%
+26.6%$2.49B$47.14M-11.794
GMTX
Gemini Therapeutics
N/A$56.91
-1.9%
N/A+32.2%$2.47BN/A-56.9130
BHC
Bausch Health Cos
2.8312 of 5 stars
$6.34
-1.3%
$7.30
+15.2%
-12.2%$2.34B$9.63B-57.5920,700Upcoming Earnings
AGIO
Agios Pharmaceuticals
4.3197 of 5 stars
$39.23
+0.5%
$58.60
+49.4%
-18.4%$2.27B$37.04M3.49390Upcoming Earnings
Analyst Forecast
TWST
Twist Bioscience
4.3598 of 5 stars
$37.80
-0.6%
$50.40
+33.3%
-38.8%$2.26B$312.97M-11.63990Positive News

Related Companies and Tools


This page (NASDAQ:STOK) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners